FDA Approval

FDA Approves PIMJETMI® Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor Merck, a leading science and technology company, announced that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor,…

Read MoreFDA Approves PIMJETMI® Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
Lab

Lab Thread Introduces AI Tools and Expands Platform Compatibility With Universal AI Assistants

Lab Thread Launches New AI Tools and Strengthens Platform With Universal AI Assistant Compatibility Lab Thread Ltd, a UK-based life science software company, announced the launch of a new Model Context Protocol (MCP) server that lets scientists connect their own…

Read MoreLab Thread Introduces AI Tools and Expands Platform Compatibility With Universal AI Assistants
Janux

Janux Therapeutics Reports Positive Initial Phase 1 Results for JANX011, Advancing Development for Autoimmune Diseases

Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease Janux Therapeutics, Inc. a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, announced initial clinical results from…

Read MoreJanux Therapeutics Reports Positive Initial Phase 1 Results for JANX011, Advancing Development for Autoimmune Diseases
Avient

Avient Partners with Albert Invent to Integrate AI-Powered Chemistry Across Global R&D Operations

Avient Teams with Albert Invent® to Bring Chemistry AI to Its Global R&D Network Avient Corporation an innovator of materials solutions, and chemistry AI company Albert Invent Corp announced a collaboration that brings AI-powered tools and modern digital infrastructure to…

Read MoreAvient Partners with Albert Invent to Integrate AI-Powered Chemistry Across Global R&D Operations

Bristol Myers Squibb Presents 56-Week Phase 3 Camzyos Data in Pediatric Patients with Obstructive Hypertrophic Cardiomyopathy at HCMS Scientific Sessions

Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Bristol Myers Squibb presented 56-week results from the Phase 3 SCOUT-HCM…

Read MoreBristol Myers Squibb Presents 56-Week Phase 3 Camzyos Data in Pediatric Patients with Obstructive Hypertrophic Cardiomyopathy at HCMS Scientific Sessions

BIOTECanada Highlights Federal Budget Support for Growth in Canada’s Life Sciences Sector

BIOTECanada: Federal Budget Builds on Momentum for Canada’s Life Sciences Sector BIOTECanada welcomes measures in Budget 2026 that can help strengthen Canada’s life sciences sector, including expanded support for research and development, new investment incentives and additional funding for strategic…

Read MoreBIOTECanada Highlights Federal Budget Support for Growth in Canada’s Life Sciences Sector

Convintro™ Herbicide Launches in the U.S., Offering a New Weed-Control Solution for Corn and Soybean Growers

First U.S. Convintro™ Herbicide Delivery Launches a New Weed-Control Option for Corn and Soybean Growers Bayer marked the first U.S. delivery of Convintro™ herbicide, transported from its Kansas City manufacturing facility to New Century FS in Ruthven, Iowa. The milestone…

Read MoreConvintro™ Herbicide Launches in the U.S., Offering a New Weed-Control Solution for Corn and Soybean Growers

German Chancellor Merz Visits Kyoto Fusioneering to Discuss Japan–Germany Collaboration in Fusion Energy

German Chancellor Merz Visits Kyoto Fusioneering, Exchanges Views on Japan–Germany Cooperation to Address Common Challenges in Fusion Energy Kyoto Fusioneering welcomed Federal Chancellor Friedrich Merz of the Federal Republic of Germany to its Tokyo headquarters and R&D center on October…

Read MoreGerman Chancellor Merz Visits Kyoto Fusioneering to Discuss Japan–Germany Collaboration in Fusion Energy
Onchilles

Onchilles Pharma Reports First Clinical Data at SITC 2026 That N17350 Could Turn One Tumor into a Personalized Cancer Vaccine

Onchilles Pharma Reports First Clinical Data at SITC 2026 That N17350 Could Turn One Tumor into a Personalized Cancer Vaccine Onchilles Pharma, a clinical-stage biotechnology company pioneering next-generation cancer therapeutics that harness the ELANE pathway, announced preliminary clinical findings from…

Read MoreOnchilles Pharma Reports First Clinical Data at SITC 2026 That N17350 Could Turn One Tumor into a Personalized Cancer Vaccine
Agenus

Agenus Reports Long-Term Survival in Over 50% of Refractory MSS Metastatic Colorectal Cancer Patients Treated with BOT+BAL at SITC 2026

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026 Agenus Inc. a leader in immuno-oncology innovation, announced new findings from a long-term survivor analysis of its Phase…

Read MoreAgenus Reports Long-Term Survival in Over 50% of Refractory MSS Metastatic Colorectal Cancer Patients Treated with BOT+BAL at SITC 2026